IgA Nephropathy Associated with Trifluridine/Tipiracil: A Case Report

Geoffroy Desbuissons; Liliane Ngango; Isabelle Brochériou; Philippe Fournier

doi:10.1159/000509375

IgA Nephropathy Associated with Trifluridine/Tipiracil: A Case Report

Nephron. 2020;144(10):506-508. doi: 10.1159/000509375. Epub 2020 Aug 14.

Authors

Geoffroy Desbuissons^{1

2}, Liliane Ngango³, Isabelle Brochériou⁴, Philippe Fournier³

Affiliations

¹ Nephrology Department, Hôpital Privé de l'Ouest Parisien, Trappes, Ramsay Santé, Trappes, France, geodesbuissons@hotmail.fr.
² Nephrology Department, Kremlin Bicêtre Hospital, Assistance Publique des Hôpitaux de Paris, Le Kremlin-Bicêtre, Le Kremlin-Bicêtre, France, geodesbuissons@hotmail.fr.
³ Nephrology Department, Hôpital Privé de l'Ouest Parisien, Trappes, Ramsay Santé, Trappes, France.
⁴ Pathology Department, Pitié-Salpêtrière Hospital, Assistance Publique des Hôpitaux de Paris, Paris, France.

PMID: 32799198
DOI: 10.1159/000509375

Abstract

Kidney diseases during chemotherapy treatment are variable, with different manifestations depending on the drugs used. Trifluridine/tipiracil is a treatment used in refractory metastatic digestive cancers. Its renal toxicity is poorly described. We report here the onset of a severe IgA nephropathy requiring hemodialysis which occurred several weeks after trifluridine/tipiracil treatment.

Keywords: IgA nephropathy; Nephrotoxicity; Trifluridine/Tipiracil.

Publication types

Case Reports

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Colonic Neoplasms / drug therapy
Glomerulonephritis, IGA / chemically induced*
Glomerulonephritis, IGA / physiopathology
Glomerulonephritis, IGA / therapy
Humans
Male
Pyrrolidines / adverse effects*
Thymine / adverse effects*
Trifluridine / adverse effects*

Substances

Pyrrolidines
tipiracil
Thymine
Trifluridine